(Reuters) – British drugmaker GSK on Friday announced positive results from its late-stage trial of asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD), also known as smoker’s lungs.
The company said the trial met its main goal in reducing the annualised rate of moderate or severe exacerbations, compared with a placebo, in COPD patients treated for up to 104 weeks.
The disease is also known as ‘smoker’s lungs’ because in western countries it primarily affects cigarette smokers.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D’Souza)
Comments